Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction.

Publication date: May 27, 2026

Coronavirus disease (COVID-19) remains a global health concern due to its high mortality and morbidity. In this study, we combined ligand-based pharmacophore modeling (LBPM) with structure-based virtual screening (SBVS) to identify novel inhibitors targeting the SARS-CoV-2 spike protein. Ligands from the MolPort database were screened via docking and molecular dynamics simulations at the receptor-binding domain (RBD). Four compounds showed promising docking scores (-8. 7 to -6. 4 kcal/mol) and dynamic stability (root mean square deviation  100 uM). These findings show the efficacy of the LBPM technique and highlight 1H-pyrazol-5-ol derivatives as potential building blocks for developing new antiviral agents against SARS-CoV-2.

Open Access PDF

Concepts Keywords
Antiviral ACE2 protein, human
Coronavirus Angiotensin-Converting Enzyme 2
Deviation100 Angiotensin-Converting Enzyme 2
Global Antiviral Agents
Ligand Antiviral Agents
Binding Sites
COVID-19
COVID-19 Drug Treatment
Drug Evaluation, Preclinical
Humans
inhibitors viral entry
Ligands
Ligands
Molecular Docking Simulation
Molecular Dynamics Simulation
Pharmacophore
pharmacophore modeling validation
Protein Binding
Pyrazoles
Pyrazoles
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Structure-Activity Relationship

Semantics

Type Source Name
pathway KEGG Coronavirus disease
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *